Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Interest Expense (Positive)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688513 Chengdu Easton Biopharmaceuticals Co Ltd SHSE:688513
84 GF Score
Price ¥51.25
GF Value ¥46.94
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Chengdu Easton Biopharmaceuticals Co Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.

SHSE:688513
84GF Score
Chengdu Easton Biopharmaceuticals Co Ltd SHSE:688513
Interest Expense (Positive) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Overvalued in 2026?

Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co stock appears to be overvalued. The current stock price of ¥51.25 is trading 9.2% above its estimated GF Value™ of ¥46.94. GuruFocus considers Chengdu Easton Biopharmaceuticals Co to be Fairly Valued.

Key valuation signals for SHSE:688513:

  • Interest Expense (Positive):
  • GF Value™: ¥46.94 vs. price of ¥51.25 (9.2% above fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the SHSE:688513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chengdu Easton Biopharmaceuticals Co Business Description

Address No. 8, Xiyuan Avenue, Chengdu High-tech Zone, Sichuan Province, Chengdu, CHN, 611731
Chengdu Easton Biopharmaceuticals Co Ltd is a Chinese pharmaceutical company engaged in the research, development, production, and sale of chemical active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio spans APIs and fixed-dose formulations, including capsules, tablets, and injections, covering therapeutic areas such as anesthesia, analgesia, and cardiovascular and anti-infective treatments. The company serves pharmaceutical manufacturers, hospitals, and healthcare distributors, primarily in the Chinese market, while also exporting APIs and intermediates to international customers. Revenue is generated through the sale of APIs and finished drug products, supported by in-house R&D and manufacturing capabilities that carry products from development through commercial-scale production. The company is listed on the Shanghai Stock Exchange's STAR Market under the ticker 688513.
84GF Score

Get the complete analysis for SHSE:688513

Interest Expense (Positive) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥51.25
Price
¥46.94
GF Value